<DOC>
	<DOCNO>NCT02338674</DOCNO>
	<brief_summary>Chronic hepatitis B patient normal ALT subjective therapeutic indication EASL Clinical Practice Guidelines . However , grow consensus long-term risk HBV infection normal ALT reach solid evidence accumulate . Moreover , large proportion hepatitis B patient normal ALT child-bearing age . Concerns impact HBV fetal neonatal health become psychological burden . Therefore , necessary explore regimen generate rapid virological response , promise e antigen conversion rate , safeguard fetus . The pre-clinical study center find group rapid decrease HBV DNA low recurrence rate discontinuation antiviral therapy combine tenofovir telbivudine ( LdT + TDF ) treatment . The current study use tenofovir telbivudine jointly immune-tolerant patient chronic hepatitis B , observe seroconversion rate , DNA decrease , proportion drug resistance , relapse rate treatment , well adverse effect .</brief_summary>
	<brief_title>TDF LdT HBV Patients With Normal ALT</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Female , age 1845 year old artificial reproductive need Liver function ( ALT ) &lt; 2ULN &gt; 2ULN ( latter include control group ) HBVDNA &gt; 10e+5 , &lt; 10e+10 HBVeAg +/ History &gt; 0.5 year Cirrhosis Combined liver disease autoimmune liver disease , alcoholic liver disease , fatty liver Liver part malignancy Bilirubin &gt; 17.1 GGT &gt; 2ULN Liver transplant patient combine HCV , HDV , HIV infection A history antiHBV drug resistance History habitual abortion previous fetal malformation history CRP &gt; 3.0ng / ml Uncontrolled hypertension Proteinuria Calculated creatinine clearance &lt; 70 mL/min Heart failure acute coronary syndrome Coagulopathy Drug alcohol addiction Hyperlipidemia LDL &gt; 4.6 TG &gt; 2.0 Alphafetoprotein &gt; 50 ng/mL Received interferon ( pegylated ) therapy within 6 month screen visit Evidence hepatocellular carcinoma Received solid organ bone marrow transplantation Was currently receive therapy immunomodulators ( eg , corticosteroid , etc . ) , investigational agent , nephrotoxic agent , agent Known hypersensitivity study drug , metabolite , formulation excipients</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>